89bio

ETNB

The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 p.

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 per sh.

On Thursday, Roche Holdings AG RHHBY agreed to acquire 89bio, Inc. ETNB for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for liver and cardiometabolic diseases.

Small biotech 89bio nearly doubled Thursday after Roche agreed to buy the MASH drug developer in a deal worth up to $3.5 billion.

As of Sept. 18, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 89bio, Inc. (NASDAQ: ETNB) to Roche is fair to 89bio shareholders. Under the terms of the proposed transaction, 89bio shareholders will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 per share in cash upon achievement of specified milestones. Halper Sadeh encourages 89bio sha.